Emyria Ltd (ASX:EMD) has received Authorised Prescriber approval from the Therapeutic Goods Administration (TGA) for MDMA-assisted therapy in treating post-traumatic stress disorder (PTSD) This means Emyria’s specialist psychiatrist can prescribe MDMA under a strict regulatory framework for PTSD care.
This is a significant milestone, as MDMA-assisted therapy is being explored as a treatment for PTSD, with multiple Phase 3 clinical trials conducted in the USA. The approval allows Emyria to expand its service offerings beyond clinical trials and into real-world treatment
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
-0.001(3.57%) |
Mkt cap ! $13.26M | |||
| Open | High | Low | Value | Volume |
| 2.8¢ | 2.9¢ | 2.7¢ | $33.97K | 1.203M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 561816 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 102456 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| EMD (ASX) Chart |